Potential of ATP5MG to Treat Metabolic Syndrome-Associated Cardiovascular Diseases

Potential of ATP5MG to Treat Metabolic Syndrome-Associated Cardiovascular Diseases

IntroductionMetabolic syndrome-associated cardiovascular disease (MetS-CVD) is a cluster of metabolism-immunity highly integrated diseases. Emerging evidence hints that mitochondrial energy metabolism may be involved in MetS-CVD development. The physiopathological role of ATP5MG, a subunit of the F0...

Full description

Bibliographic Details
Main Authors: Lianyong Liu, Xinglu Zhou, Juan Chen, Xiangqi Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
cardiovascular disease
metabolic syndrome
drug
ATP5L
ceRNA
inflammation
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.921778/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.921778/full

Similar Items